Cognitive Function Dynamics During Folate Augmented Therapy in Patients with Schizophrenia Carrying MTHFR677C>T Gene Polymorphism: a Pilot Study

The aim of the investigation is to study the carriage of alleles of folate cycle MTHFR677C>T polymorphism and to assess cognitive function dynamics in the course of folate augmented antipsychotic therapy in schizophrenic patients carrying defective MTHFR677T allele.

Materials and Methods. 129 patients with schizophrenia underwent molecular diagnosing of 677C>T polymorphism in MTHFR folate metabolism gene using PCR method with allele-specific primers and the following on-line detection. Of them 18 patients carrying defective T allele received antipsychotic therapy augmented by folates. The patients were tested with a standard battery of cognitive tests before and after augmentation. Patients of the control group (n=13) comparable with the main one in gender, age, psychic condition were subject to the same procedures, but did not receive folates. The level of plasma homocysteine was determined in 7 patients.

Results. Carriage of defective T allele of MTHFR677C>T polymorphism was found in more than half the examined patients, more often than in the general population, though being not statistically significant for such a quantity of observations. Improvement of cognitive functioning was noted in those having defective T allele and receiving folates: short-term auditory memory (p<0.05), phonetic verbal fluency (p<0.05), problem-solving behavior (p<0.05), visual-motor coordination (p<0.01), rigidity (p<0.05), motor velocity (p<0.05), working memory, attention selectivity and distribution (p<0.05). The cognitive function dynamics was more pronounced in the main group than in the control one, however in some patients exacerbation of productive symptoms was observed. Augmentation by folates was most effective in patients with homozygous carriage of the defective T allele and hyperhomocysteinemia before intervention.

Conclusion. Augmentation of antipsychotic therapy by folates may appear to be a promising strategy for improving cognitive functions in patient with schizophrenia having folate metabolism impairments, which requires personified approach with biomarker study before intervention.

1. Muntjewerff J.W., Kahn R.S., Blom H.J., den Heijer M. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry 2006; 11(2): 143–149, http://dx.doi.org/10.1038/sj.mp.4001746.
2. Zhilyaeva T.V. One-carbon metabolism impairment in schizophrenia. Psikhiatriya i psikhofarmakoterapiya im. P.B. Gannushkina 2012; 14(6): 41–46.
3. Babunova N.B. Izuchenie assotsiatsii genov AGT, AGT1R i MTHFR s serdechno-sosudistymi zabolevaniyami. Dis. ... kand. biol. nauk [The study of AGT, AGT1R and MTHFR gene associations with cardiovascular diseases. PhD Dissertation]. Moscow; 2004.
4. Kalashnikova E.A., Kokarovtseva S.N. Association between congenital thrombophilia and fetal loss in russian population. Meditsinskaya genetika 2005; 4(8): 386–390.
5. Miktadova A.V., Kovalenko K.A., Baronyan E.S., Mashkina E.V., Shkurat T.P. Analysis of alleles frequencies of candidate genes in Rostov on Don. Sovremennye problemy nauki i obrazovaniya 2012; 5: 276–285.
6. Botto L.D., Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and con congenital anomalies: a HuGE review. Am J Epidemiol 2000; 151(9): 862–877, http://dx.doi.org/10.1093/oxfordjournals.aje.a010290.
7. Leclerc D., Wilson A., Dumas R., Gafuik C., Song D., Watkins D., Heng H.H., Rommens J.M., Scherer S.W., Rosenblatt D.S., Gravel R.A. Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. Proc Natl Acad Sci USA 1998; 95(6): 3059–3064, http://dx.doi.org/10.1073/pnas.95.6.3059.
8. Chowdary D., Streck D., Schwalb M.N., Dermody J.J. High incidence of two methylenetetrahydrofolate reductase mutations (C677T and A1298C) in Hispanics. Genet Test 2003; 7(3): 255–257, http://dx.doi.org/10.1089/109065703322537296.
9. Peerbooms O.L., van Os J., Drukker M., Kenis G., Hoogveld L., de Hert M., Delespaul P., van Winkel R., Rutten B.P. Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: evidence for a common genetic vulnerability? Brain Behav Immun 2011, 25(8): 1530–1543, http://dx.doi.org/10.1016/j.bbi.2010.12.006.
10. Allen N.C., Bagade S., McQueen M.B., Ioannidis J.P., Kavvoura F.K., Khoury M.J., Tanzi R.E., Bertram L. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 2008; 40(7): 827–834, http://dx.doi.org/10.1038/ng.171.
11. van den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull 2010; 36(2): 246–270, http://dx.doi.org/10.1093/schbul/sbp132.
12. Roffman J.L., Brohawn D.G., Nitenson A.Z., Macklin E.A., Smoller J.W., Goff D.C. Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia. Schizophr Bull 2011; 39(2): 330–338, http://dx.doi.org/10.1093/schbul/sbr150.
13. Godfrey P.S., Toone B.K., Carney M.W., Flynn T.G., Bottiglieri T., Laundy M., Chanarin I., Reynolds E.H. Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990; 336(8712): 392–395, http://dx.doi.org/10.1016/0140-6736(90)91942-4.
14. Hill M., Shannahan K., Jasinski S., Macklin E.A.,4 Raeke L., Roffman J.L., Goff D.C. Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res 2011; 127(1–3): 41–45, http://dx.doi.org/10.1016/j.schres.2010.12.006.
15. Roffman J.L., Lamberti J.S., Achtyes E., Macklin E.A., Galendez G.C., Raeke L.H., Silverstein N.J., Smoller J.W., Hill M., Goff D.C. Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry 2013; 70(5): 481–489, http://dx.doi.org/10.1001/jamapsychiatry.2013.900.
16. Levine J., Stahl Z., Sela B.A., Ruderman V., Shumaico O., Babushkin I., Osher Y., Bersudsky Y., Belmaker R.H. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry 2006; 60(3): 265–269, http://dx.doi.org/10.1016/j.biopsych.2005.10.009.
17. Balk E.M., Raman G., Tatsioni A., Chung M., Lau J., Rosenberg I.H. Vitamin B6, B12, and folic acid supplementation and cognitive function: a systematic review of randomized trials. Arch Intern Med 2007; 167(1): 21–30, http://dx.doi.org/10.1001/archinte.167.1.21.
18. Sarkisyan G.R., Gurovich I.Ya., Keefe R.S. Normative data for the russian population and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS) Scale. Sotsial’naya i klinicheskaya psikhiatriya 2010; 20(3): 13–19.
19. Fetisova I.N., Dobrolyubov A.S., Lipin M.A., Polyakov A.V. The polymorphism of folate metabolism genes and human diseases. Vestnik novykh meditsinskikh tekhnologiy 2007; Х(1): 32–38.
20. Gnezdilova I.V., Akhmadishina L.Z. The study of methylenetetrahydrofolate reductase (MTHFR) gene role in the formation of susceptibility to thrombophilia. Molodoy uchenyy 2010; 1(2–1): 123–126.

Zhilyaeva T.V., Sergeyeva A.V., Kasimova L.N., Blagonravova A.S. Cognitive Function Dynamics During Folate Augmented Therapy in Patients with Schizophrenia Carrying MTHFR677C>T Gene Polymorphism: a Pilot Study. Sovremennye tehnologii v medicine 2015; 7(4): 147, https://doi.org/10.17691/stm2015.7.4.20